News

News Subscription

Nov 02. 2017
Basilea reports on commercial progress of antifungal Cresemba® in Europe
Read more
Download
Oct 31. 2017
Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
Read more
Download
Oct 23. 2017
Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
Read more
Download
Sep 28. 2017
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
Read more
Download
Sep 12. 2017
Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
Read more
Download
Aug 10. 2017
Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
Read more
Download
Jul 20. 2017
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
Read more
Download
Jun 15. 2017
Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
Read more
Download
Jun 14. 2017
Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
Read more
Download
Jun 13. 2017
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
Read more
Download